Introduction
============

Nasopharyngeal carcinoma (NPC), a malignant tumor arising from the epithelium of the nasopharynx, is the most prevalent in southern China ([@b1-ol-0-0-7083]). In Hong Kong, the incidence of NPC is as high as 0.02--0.03% in males and 0.01--0.02% in females ([@b2-ol-0-0-7083]). Although the classic treatment of high-dose radiotherapy plus adjunctive chemotherapy is able to achieve a 5-year survival rate of 80%, recurrence and metastasis may occur, which are the primary causes of mortality ([@b3-ol-0-0-7083]). Therefore, it is necessary to identify molecular biomarkers for NPC prognosis and targeted therapy.

Aberrant DNA methylation usually leads to the occurrence of tumors. CpG island promoter hypermethylation and global DNA hypomethylation are the characteristics of the cancer epigenome ([@b4-ol-0-0-7083],[@b5-ol-0-0-7083]). In NPC, aberrant methylation has been considered as the most frequent event for gene silencing: For example, a previous study identified that abnormal methylation on chromosome 6p occurs in 76.9% of patients with early-stage NPC, based on the comparative methylome analysis ([@b6-ol-0-0-7083]). Furthermore, tumor-suppressor genes such as protocadherin 8 (*PCDH8*), FEZ family zinc finger 2 (*FEZF2*) and argininosuccinate synthetase (*ASS1*) have been previously demonstrated to be frequently methylated in NPC, which promotes NPC cell migration, and are associated with poorer clinical outcomes ([@b7-ol-0-0-7083]--[@b9-ol-0-0-7083]).

With the exception of DNA methylation, the differential expression of genes is also frequently detected in NPC: A previous study demonstrated that the overexpression of branched-chain-amino-acid aminotransferase cytosolic (BCAT1) protein in NPC at different pathological stages and BCAT1 deficiency reduced tumor cell proliferation and decreased cell migration and invasion abilities ([@b10-ol-0-0-7083]). Recently, upregulation of Kelch domain containing 4 (*KLHDC4*) was demonstrated to result in poor overall and metastasis-free survival rates, and the deletion of *KLHDC4* significantly induced the spontaneous apoptosis of NPC cells ([@b11-ol-0-0-7083]). However, the molecular mechanisms of NPC remain incompletely understood. There have been no studies that have comprehensively analyzed differentially expressed methylated genes using array data from multiple platforms.

In the present study, methylation profiling data in the dataset GSE62336 ([@b6-ol-0-0-7083]), sourced from the Gene Expression Omnibus (GEO) database, were used to identify differentially methylated regions (DMRs) and differentially methylated CpG islands (DMIs). Concurrently, compared with differentially expressed genes (DEGs) that were identified using a meta-analysis of three gene expression datasets (GSE53819, GSE13597 and GSE12452) ([@b12-ol-0-0-7083]--[@b14-ol-0-0-7083]), differentially methylated genes were identified. Additionally, a functional network consisting of the differentially methylated genes was constructed to reveal the potential functional associations of those genes. These results may provide novel information for the study of molecular mechanisms underlying NPC and provide potential therapeutic targets for NPC.

Materials and methods
=====================

### Data acquisition

Methylation profiling data from the dataset GSE62336 ([@b6-ol-0-0-7083]) were downloaded from GEO (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b15-ol-0-0-7083]). A total of 25 primary NPC tumors and non-tumor counterparts were included in this dataset, and the data were produced on the platform of Illumina HumanMethylation450 BeadChip (GPL13534, HumanMethylation450_15017482) (Illumina, Inc., San Diego, CA, USA).

Three gene expression profiling datasets (GSE53819, GSE13597 and GSE12452) were obtained from GEO. In the GSE53819 dataset ([@b13-ol-0-0-7083]), 18 primary NPC tumors and 18 non-cancerous nasopharyngeal tissues were included; the median ages were 46 years (range, 19--77 years) for patients with NPC, and 45 years (range, 18--78 years) for the non-cancerous cohort; almost one third of patients were females; all samples were collected prior to any anticancer treatment. Data in the GSE53819 dataset were produced on the platform of Agilent-014850 Whole Human Genome Microarray 4×44 K G4112F (Probe Name version; GPL6480; Agilent Technologies, Inc., Santa Clara CA, USA). The GSE13597 dataset ([@b14-ol-0-0-7083]) contained data of 25 histologically confirmed undifferentiated NPC tissues and 3 non-malignant nasopharyngeal controls, which were produced on the platform of \[HG-U133A\] Affymetrix Human Genome U133A Array (GPL96) (Affymetrix, Inc., Santa Clara, CA, USA). Additionally, the GSE12452 dataset ([@b12-ol-0-0-7083]) contained 31 NPC tumor samples and 10 normal healthy nasopharyngeal tissues, data of which were produced on the platform of \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array (GPL570) (Affymetrix, Inc.).

### Data preprocessing

The downloaded raw data were preprocessed. For the methylation data in GSE62336, documents of normalized average β-value were downloaded. The β-mixture quantile normalization method (BMIQ) ([@b16-ol-0-0-7083]) was utilized to preprocess β-values.

Due to different platforms being used for the three gene expression profiling datasets, two different methods were utilized for data preprocessing. For the gene expression data in the GSE13597 and GSE12452 datasets, raw gene expression data were preprocessed using the method of robust microarray analysis in Affy package (version 1.46.1; <https://www.bioconductor.org/packages/3.1/bioc/html/affy.html>) in R ([@b17-ol-0-0-7083]). The preprocessing steps included background correction, quantile normalization and calculation of expression. By contrast, Limma (version 3.24.15; <https://www.bioconductor.org/packages/3.1/bioc/html/limma.html>) package ([@b18-ol-0-0-7083]) in R was applied to preprocess raw data in the GSE53819 dataset. The preprocessing steps included background correction, normalization between arrays and concentration of microarray data. Following this, an annotation file of the platform corresponding to each dataset was used for the transformation of probe identities into gene symbols. If one probe corresponded to multiple genes, the expression value of this probe would be removed. However, if multiple probes corresponded to a certain gene, the mean expression value was defined as the final expression value of the gene.

### Prediction of DMRs and DMIs

DMRs between NPC and normal samples were predicted using COHCAP package (version 1.6.0; <http://www.bioconductor.org/pacages/3.1/bioc/html/COHCAP.html>) ([@b19-ol-0-0-7083]) in R. Briefly, based on the β-value file of CpG site probes, Δβ, P-value and adjusted P-value of NPC and normal samples were calculated by COHCAP. Only regions with \|Δβ\|\>0.1 and adjusted P\<0.05 were identified as DMRs.

Furthermore, the COHCAP package was also utilized to predict DMIs. CpG island statistics were calculated by averaging β-values among samples per site and comparing the average β-values across groups. If the number of DMRs in the CpG island was \>4, this CpG island was identified as a DMI.

### Identification of DEGs using meta-analysis

MetaDE package (version 1.1.6; <http://www.bioconductor.org/packages/2.11/bioc/html/metahdep.html>) ([@b20-ol-0-0-7083]) in R was applied to integrate DEGs in the three gene expression profiling datasets. Briefly, a heterogeneity test for each gene under different platforms was firstly performed to evaluate whether each gene was homogeneous and unbiased. If the parameter tau2=0 and Qpval\>0.05 (tau2 is used to estimate amount of heterogeneity; Qpval represents P-value of Qval test statistics; and Q is a statistical magnitude in statistics), the gene was homogeneous and unbiased. Then, the differential expression of the genes was analyzed. Only genes with P\<0.05 were considered significant. Finally, the relative fold-change (FC) in expression of each gene between the NPC tissues samples and normal control samples was calculated. Collectively, genes with P\<0.05 were identified as DEGs.

### Gene Ontology (GO) functional and pathway enrichment analyses

The gene functional analysis tool Database for Annotation, Visualization and Integrated Discovery (<http://david.abcc.ncifcrf.gov/>) ([@b21-ol-0-0-7083]) was used to perform GO \[including biological process (BP), cell component (CC) and molecular function (MF)\] and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of DEGs. Only the GO and pathway terms with gene count ≥2 and P\<0.05 were considered significant.

### Selection of DEGs with DMRs

Based on the gene symbols corresponding to the DMRs and identified DEGs, the overlapped genes between genes with hypermethylated DMRs and downregulated DEGs, and the genes with hypomethylated DMRs and upregulated DEGs were selected.

### Functional association analysis of the DEGs with DMRs

The GeneMANIA prediction server ([@b22-ol-0-0-7083],[@b23-ol-0-0-7083]) (<http://apps.cytoscape.org/download/stats/genemania/>), a plugin in Cytoscape software (version 3.2.1; National Institute of General Medical Sciences, Seattle, WA, USA), was utilized to analyze the correlations among the identified DEGs that had DMRs, based on a large set of functional association data, including protein and genetic interactions, co-expression, co-localization pathways, and protein domain similarity.

Results
=======

### Statistics of DMRs, DMIs and DEGs

In total, 2,262 probes of DMRs were obtained, including 2,234 hypermethylated CpG site probes corresponding to 1,676 gene symbols and 28 hypomethylated CpG site probes corresponding to 28 gene symbols. Furthermore, 2,983 DEGs were identified, including 1,655 upregulated and 1,328 downregulated genes. Additionally, 17 DMIs were identified, and all of them were hypermethylated in the NPC samples compared with their methylation status in the controls ([Fig. 1](#f1-ol-0-0-7083){ref-type="fig"}). Among them, dual specificity phosphatase 6 (*DUSP6*) and tenascin XB (*TNXB*) were also identified as DEGs.

### Significant pathways enriched by DEGs

In order to investigate the potential pathways associated with the identified DEGs, KEGG pathway enrichment analysis was conducted. The upregulated DEGs were primarily associated with pathways in cancer, oxidative phosphorylation and the cell cycle ([Fig. 2A](#f2-ol-0-0-7083){ref-type="fig"}). The downregulated DEGs were primarily associated with the regulation of actin cytoskeleton, chemokine signaling pathway and focal adhesion ([Fig. 2B](#f2-ol-0-0-7083){ref-type="fig"}).

### Overlapped genes between genes with DMRs and DEGs

In order to reveal whether the genes with DMRs were DEGs, genes with DMRs were compared with DEGs. It was identified that 135 genes with hypermethylated DMRs were downregulated in the NPC samples compared with their expression levels in the normal controls, including prostaglandin D2 synthase, elongation factor for RNA polymerase II 3, ATPase sarcoplasmic/endoplasmic reticulum Ca^2+^ transporting 3 and claudin 3 ([Table I](#tI-ol-0-0-7083){ref-type="table"}).

However, the 28 genes with hypomethylated DMRs were not differentially expressed between the two group samples.

### Functional associations of the DEGs with DMRs

In order to reveal the potential functional associations among the above 135 hypermethylated DEGs, a functional network was constructed ([Fig. 3](#f3-ol-0-0-7083){ref-type="fig"}). In the network, 154 genes and 1,651 association pairs were included. The association pairs included 1,155 co-expression associations, 24 physical interactions, 351 genetic interactions, 83 co-localization associations and 38 associations between shared protein domains. For example, *DUSP6* was predicted to exhibit genetic interactions with other hypermethylated DEGs such as malic enzyme 3 (*ME3*) and ST3 β-galactoside α-2,3-sialytansferase 5 (*ST3GAL5*); *TNXB* was predicted to be co-expressed with genes such as EPH receptor B6 (*EPHB6*), aldehyde dehydrogenase 1 family, member L1 (*ALDH1L1*) and glutathione peroxidase 3 (*GPX3*).

According to the enrichment analysis, the 135 hypermethylated DEGs were significantly associated with the GO functions of protein amino acid phosphorylation and phosphate metabolic process, and the tight junction pathway ([Table II](#tII-ol-0-0-7083){ref-type="table"}).

Discussion
==========

In the present study, 2,234 hypermethylated CpG site probes corresponding to 1,676 gene symbols, 28 hypomethylated CpG site probes corresponding to 28 gene symbols and 17 DMIs were identified based on analysis of the methylation profiling dataset. Furthermore, 2,983 DEGs (1,655 upregulated and 1,328 downregulated) were identified based on the three gene expression profiling datasets. Among these DEGs, 135 downregulated genes were hypermethylated, including *DUSP6* and *TNXB*, which were also among the 17 DMIs identified.

*DUSP6* encodes dual specificity phosphatase 6, also termed mitogen-activated protein kinase phosphatase 3, which belongs to the dual specificity protein phosphatase subfamily ([@b24-ol-0-0-7083]). Phosphatases in this family inactivate their target kinases, such as members of the mitogen-activated protein kinase superfamily, which are involved in cellular proliferation and differentiation ([@b25-ol-0-0-7083]). In the present study, *DUSP6* was identified to be hypermethylated and downregulated in NPC samples compared with its methylation status in the normal controls, which was consistent with other studies ([@b14-ol-0-0-7083],[@b26-ol-0-0-7083]). *DUSP6* has been identified as a tumor suppressor, and it is able to inhibit epithelial-mesenchymal transition (EMT) and cell invasion by negatively modulating the activity of extracellular-signal-regulated kinase in NPC ([@b26-ol-0-0-7083]). In the present study, *DUSP6* was predicted to exhibit genetic interactions with other hypermethylated DEGs such as *ME3* and *ST3GAL5*. *ME3* is a mitochondrial nicotinamide adenine dinucleotide phosphate^(+)^ -dependent enzyme ([@b27-ol-0-0-7083]), and it serves a unique role in tumor mitochondria ([@b28-ol-0-0-7083]). The protein encoded by *ST3GAL5* is a sialyltransferase, a type II membrane protein that catalyzes the formation of α-2,3-sialyltransferase (GM3), a protein participating in cell differentiation and cell adhesion ([@b29-ol-0-0-7083]). There is no other evidence to indicate the associations of *ME3* and *ST3GAL5* with NPC at present. Therefore, *ME3* and *ST3GAL5* may be potential novel biomarker molecules in the progression of NPC.

*TNXB* was also identified to be hypermethylated and downregulated in NPC samples compared with its methylation status in the normal controls, which was consistent with previous studies ([@b6-ol-0-0-7083],[@b12-ol-0-0-7083]). In Epstein-Barr virus-positive gastric cancer and pancreatic cancer, *TNXB* was also hypermethylated ([@b30-ol-0-0-7083],[@b31-ol-0-0-7083]). *TNXB* encodes a tenascin, which exhibits an anti-adhesive effect ([@b32-ol-0-0-7083]). It is able to promote EMT by activating latent transforming growth factor-β ([@b33-ol-0-0-7083]). In malignancy, *TNXB* is usually suppressed, and it has been identified as a marker for malignant mesothelioma ([@b34-ol-0-0-7083]). Furthermore, in the present study, *TNXB* was predicted to be co-expressed with a set of other hypermethylated DEGs, including *EPHB6, ALDH1L1* and *GPX3*. EPH receptor B6 (*EPHB6*) encodes a transmembrane protein, which may affect cell adhesion and migration. In tumor progression, *EPHB6* is usually downregulated due to promoter DNA hypermethylation ([@b35-ol-0-0-7083],[@b36-ol-0-0-7083]). It has been suggested that *EPHB6* alters invasiveness, and is associated with the prognosis and/or diagnosis of breast carcinoma ([@b35-ol-0-0-7083],[@b37-ol-0-0-7083]). *ALDH1L1* and *GPX3* have been previously identified to be silenced by methylation, which is associated with tumorigenesis ([@b38-ol-0-0-7083],[@b39-ol-0-0-7083]). Although there is no experimental evidence to confirm the involvement of *EPHB6, ALDH1L1* and *GPX3* in NPC, the present study hypothesizes that these molecules may also serve a significant role in the progression of NPC, along with *TNXB*.

Additionally, there are several limitations in the present study. The expression levels and methylation status of the aforementioned genes are required to be validated using experiments. Functional associations of these genes also need to be confirmed. These validations will be performed and presented separately. Despite the absence of experiments, several genes such as *ME3, ST3GAL5, EPHB6, ALDH1L1* and *GPX3* were primarily identified to be potentially associated with NPC, and they may become novel therapeutic targets for NPC, once validated.

In conclusion, based on the comprehensive analysis of methylation profiling and gene expression profiling, 135 downregulated genes were identified to be hypermethylated in NPC compared with its methylation status in the controls in the present study. Among them, *DUSP6* and *TNXB* contained DMIs. Hypermethylated DEGs that exhibited genetic interactions with *DUSP6*, including *ME3* and *ST3GAL5*, and genes that co-expressed with *TNXB*, including *EPHB6, ALDH1L1* and *GPX3*, may be potential novel molecules involved in the progression of NPC, and they may become novel therapeutic targets for NPC.
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![Kyoto Encyclopedia of Genes and Genomes pathway terms that were significantly enriched by differentially expressed genes. Pathway terms enriched by (A) upregulated and (B) downregulated genes. hsa, Homo sapiens.](ol-14-06-7171-g01){#f2-ol-0-0-7083}

![Functional network displaying functional associations of the 135 differentially hypermethylated genes. Green nodes with red outer ring represent the downregulated genes containing hypermethylated regions, while grey nodes represent the non-differentially expressed genes.](ol-14-06-7171-g02){#f3-ol-0-0-7083}

###### 

Information regarding the downregulated genes containing hypermethylated regions.

  Site ID      Chr   Loc         Gene        Island                     Mean log~2~FC^[a](#tfn1-ol-0-0-7083){ref-type="table-fn"}^   Mean β-value in NPC samples   Mean β-value in normal samples   Δβ (NPC vs. normal)   FDR (NPC vs. normal)
  ------------ ----- ----------- ----------- -------------------------- ------------------------------------------------------------ ----------------------------- -------------------------------- --------------------- ----------------------
  cg20450318   11    65415260    *SIPA1*     chr11:65413778-65415203    −0.72                                                        6.57×10^−1^                   4.65×10^−1^                      1.92×10^−1^           1.30×10^−4^
  cg17953300   11    65418265                chr11:65419853-65420527                                                                 5.91×10^−1^                   4.57×10^−1^                      1.34×10^−1^           2.33×10^−3^
  cg16915828   11    73371940    *PLEKHB1*   chr11:73371800-73372632    −0.59                                                        6.19×10^−1^                   4.31×10^−1^                      1.88×10^−1^           2.93×10^−5^
  cg07223180   13    20989142    *CRYL1*     chr13:20989007-20989836    −0.62                                                        5.98×10^−1^                   4.63×10^−1^                      1.35×10^−1^           5.69×10^−5^
  cg21177426   15    37386586    *MEIS2*     chr15:37387386-37387614    −0.82                                                        6.28×10^−1^                   4.68×10^−1^                      1.60×10^−1^           1.70×10^−5^
  cg24361265   15    44068668    *EL*L3      chr15:44068586-44069792    −1.24                                                        6.36×10^−1^                   4.32×10^−1^                      2.04×10^−1^           2.51×10^−5^
  cg06786050   16    84401247    *ATP2C2*    chr16:84401957-84402497    −0.82                                                        5.58×10^−1^                   4.36×10^−1^                      1.22×10^−1^           1.21×10^−4^
  cg26824780   16    89004908    *CBFA2T3*   chr16:89006334-89008600    −0.87                                                        5.95×10^−1^                   4.73×10^−1^                      1.23×10^−1^           6.23×10^−6^
  cg09013975   17    3847872     *ATP2A3*    chr17:3847999-3848570      −1.06                                                        6.68×10^−1^                   4.90×10^−1^                      1.78×10^−1^           4.51×10^−5^
  cg05247914   19    35629701    *FXYD1*     chr19:35632356-35632572    −0.62                                                        6.76×10^−1^                   4.83×10^−1^                      1.93×10^−1^           3.71×10^−5^
  cg03078169   19    35629791                chr19:35632356-35632572                                                                 6.31×10^−1^                   4.79×10^−1^                      1.52×10^−1^           4.40×10^−5^
  cg27461196   19    35630106                chr19:35632356-35632572                                                                 5.59×10^−1^                   4.51×10^−1^                      1.08×10^−1^           1.81×10^−4^
  cg16334795   21    42538894    *BACE2*     chr21:42539367-42540872    −0.86                                                        6.06×10^−1^                   4.51×10^−1^                      1.55×10^−1^           1.58×10^−5^
  cg08481491     3   125900108   *ALDH1L1*   chr3:125898662-125899568   −0.80                                                        5.85×10^−1^                   4.46×10^−1^                      1.38×10^−1^           1.04×10^−4^
  cg04161526     6   31696519    *DDAH2*     chr6:31695894-31698245     −0.63                                                        5.65×10^−1^                   4.33×10^−1^                      1.32×10^−1^           2.25×10^−5^
  cg21286967     6   31696710                chr6:31695894-31698245                                                                  6.01×10^−1^                   4.71×10^−1^                      1.30×10^−1^           3.27×10^−5^
  cg25526039     6   107813291   *SOBP*      chr6:107810066-107812733   −0.81                                                        5.53×10^−1^                   4.36×10^−1^                      1.17×10^−1^           4.45×10^−4^
  cg24419391     7   73183516    *CLDN3*     chr7:73183379-73185115     −1.02                                                        5.89×10^−1^                   4.67×10^−1^                      1.21×10^−1^           1.64×10^−3^
  cg08580268     7   150038502   *RARRES2*   chr7:150037459-150039031   −0.94                                                        5.66×10^−1^                   3.95×10^−1^                      1.71×10^−1^           9.63×10^−5^
  cg27494647     7   150038898               chr7:150037459-150039031                                                                6.14×10^−1^                   4.15×10^−1^                      1.99×10^−1^           7.82×10^−5^
  cg11714502     9   130640212   *AK1*       chr9:130639738-130640143   −0.61                                                        5.71×10^−1^                   4.47×10^−1^                      1.24×10^−1^           5.00×10^−4^
  cg02156769     9   139872246   *PTGDS*     chr9:139872237-139873143   −1.81                                                        5.58×10^−1^                   4.56×10^−1^                      1.01×10^−1^           1.95×10^−5^
  cg07390373     X   43741933    *MAOB*      chrX:43741299-43741827     −0.78                                                        5.96×10^−1^                   4.88×10^−1^                      1.08×10^−1^           3.94×10^−5^
  cg05605944     X   43741945                chrX:43741299-43741827                                                                  5.84×10^−1^                   4.62×10^−1^                      1.22×10^−1^           1.72×10^−5^

This table lists the genes with \|log~2~ FC\|\>0.58. Site ID, probe identity of CpG site; Chr, chromosome where probe is located; Loc, location of probe; FC, fold-change; NPC, nasopharyngeal carcinoma; FDR, false discovery rate.

###### 

Results of GO and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses of the 135 downregulated genes containing hypermethylated regions.

  Category   Term                                                                      P-value   Gene count   Genes
  ---------- ------------------------------------------------------------------------- --------- ------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BP         GO:0006468\~protein amino acid phosphorylation                            0.0021    14           *STK10, DRD4, PTPRA, MKNK2, PRKCH, ADRBK1, FES, TRIB2, CSNK2A2, EPHB6, TNK2, CD6, MAP3K12, AKT2*
             GO:0006796\~phosphate metabolic process                                   0.0087    16           *STK10, DRD4, EPM2A, PTPRA, MKNK2, PRKCH, ADRBK1, FES, TRIB2, CSNK2A2, EPHB6, TNK2, CD6, MAP3K12, AKT2, DUSP6*
             GO:0006793\~phosphorus metabolic process                                  0.0087    16           *STK10, DRD4, EPM2A, PTPRA, MKNK2, PRKCH, ADRBK1, FES, TRIB2, CSNK2A2, EPHB6, TNK2, CD6, MAP3K12, AKT2, DUSP6*
             GO:0016310\~phosphorylation                                               0.0096    14           *STK10, DRD4, PTPRA, MKNK2, PRKCH, ADRBK1, FES, TRIB2, CSNK2A2, EPHB6, TNK2, CD6, MAP3K12, AKT2*
             GO:0006357\~regulation of transcription from RNA polymerase II promoter   0.0113    13           *CDKN1C, GATA2, SORBS3, MEIS2, E2F4, CRTC1, TFAP2B, GFI1, TCEA2, LRRFIP1, ELL3, NtnxbR0B1, ZBTB38*
  CC         GO:0044459\~plasma membrane part                                          0.0118    27           *FXYD1, OCLN, CLDN3, SLC6A20, DRD4, ADRBK1, PRR7, SORBS3, EPHB6, ANK1, ST3GAL5, ITGB7, GRIN2D, CD6, SLC43A1, KCNQ1, SLC1A1, HCN2, CR1, PTPRA, MAOB, TSPAN13, ACTN3, LSP1, AP2A2, MPL, SPTAN1*
             GO:0005887\~integral to plasma membrane                                   0.0166    17           *FXYD1, HCN2, CR1, CLDN3, SLC6A20, DRD4, PTPRA, TSPAN13, EPHB6, ST3GAL5, GRIN2D, ITGB7, MPL, CD6, KCNQ1, SLC1A1, SLC43A1*
             GO:0031226\~intrinsic to plasma membrane                                  0.0201    17           *FXYD1, HCN2, CR1, CLDN3, SLC6A20, DRD4, PTPRA, TSPAN13, EPHB6, ST3GAL5, GRIN2D, ITGB7, MPL, CD6, KCNQ1, SLC1A1, SLC43A1*
             GO:0005626\~insoluble fraction                                            0.0247    13           *DES, JPH2, BACE2, GRIN2D, EPHX1, TSPAN13, ADRBK1, LTC4S, NR0B1, SLC1A1, MAP3K12, SPTAN1, AKT2*
             GO:0000267\~cell fraction                                                 0.0336    15           *JPH2, TSPAN13, EPHX1, ADRBK1, LTC4S, NR0B1, DES, BACE2, GRIN2D, GPX3, SLC1A1, MAP3K12, AKT2, SPTAN1, DUSP6*
  MF         GO:0008134\~transcription factor binding                                  0.0009    13           *ZNF274, E2F4, CRTC1, NR0B1, GATA2, SORBS3, MEIS2, DIP2C, NCOA4, GPX3, TFAP2B, SOX17, DDAH2*
             GO:0048037\~cofactor binding                                              0.0156      7          *SDHA, CRYL1, ME3, ALDH1L1, ACADS, GPT, OAT*
             GO:0005200\~structural constituent of cytoskeleton                        0.0220      4          *SORBS3, ANK1, DES, SPTAN1*
             GO:0004672\~protein kinase activity                                       0.0247    11           *CSNK2A2, EPHB6, STK10, MKNK2, PRKCH, ADRBK1, TNK2, FES, MAP3K12, TRIB2, AKT2*
  Pathway    hsa04530: Tight junction                                                  0.0036      7          *CSNK2A2, OCLN, CLDN3, PRKCH, ACTN3, SPTAN1, AKT2*

BP, biological process; CC, cell component; MF, molecular function; GO, Gene Ontology; hsa, *Homo sapiens*.
